➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Merck
Medtronic
Baxter
Colorcon

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

HYLENEX RECOMBINANT Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for HYLENEX RECOMBINANT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
New York University School of MedicinePhase 2
National Institutes of Health (NIH)Phase 2
Steve Yoelin M.D. Medical Associates, Inc.Phase 1

See all HYLENEX RECOMBINANT clinical trials

Recent Litigation for HYLENEX RECOMBINANT

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19
Halozyme, Inc. v. Lee2016-12-18

See all HYLENEX RECOMBINANT litigation

Company Disclosures: US Patents for HYLENEX RECOMBINANT

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 001 2005-12-02   Get Started Free Halozyme, Inc. (San Diego, CA) 2039-09-22 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 001 2005-12-02   Get Started Free Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 001 2005-12-02   Get Started Free Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 001 2005-12-02   Get Started Free Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for HYLENEX RECOMBINANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2016022 Lithuania   Get Started Free PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
CA 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
92780 Luxembourg   Get Started Free PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
CA 2015 00043 Denmark   Get Started Free PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
CR 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
122015000061 Germany   Get Started Free PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
Boehringer Ingelheim
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.